| Nov 12 |
Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants
|
| Nov 12 |
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
|
| Nov 11 |
Avalo Therapeutics to Present at Upcoming Investor Conferences
|
| Nov 7 |
Avalo Therapeutics GAAP EPS of -$2.83, revenue of $0.25M
|
| Nov 7 |
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
|
| Oct 8 |
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
|
| Sep 4 |
Avalo Announces Participation in September Investor Conferences
|
| Aug 12 |
Avalo Therapeutics GAAP EPS of -$14.07
|
| Aug 12 |
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
| Jul 16 |
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
|
